Education
About Us
Working with TipRanks
Follow Us
Heron Therapeutics (HRTX)
NASDAQ:HRTX
Earnings Data
Report Date
May 11, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.01Last Year’s EPS
0.01Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call communicated strong commercial inflection and financial progress: record annual revenue (~$155M), improved gross margin (~73%), and adjusted EBITDA of $14.7M, alongside clear Q4 momentum in Acute Care driven by ZYNRELEF (+48% YoY) and APONVIE (+97% YoY). Operational wins (financing completion, J-codes, VAN rollout, CrossLink IGNITE, guideline inclusion) support continued growth. Key risks include ongoing Oncology headwinds from the SUSTOL wind-down (7.8% YoY decline in Oncology revenue), pricing pressure and competition for CINVANTI, the multi-year timeline for ZYNRELEF PFS approval, the need to educate providers on the NOPAIN Act, and litigation uncertainty. Management expects to remain EBITDA positive in 2026 while making targeted commercial investments that may temporarily moderate near-term EBITDA but aim to accelerate longer-term revenue and value creation.Company Guidance
Record Annual Revenue and Improved Profitability
Full year 2025 net product sales of $154.9 million and adjusted EBITDA of $14.7 million (more than doubling prior year performance), beating prior guidance of $9M–$13M. Gross margin approximately 73%, reflecting improved cost discipline and favorable product mix.
Acute Care Quarter Acceleration
Acute Care net sales of $16.3 million in Q4 2025, up ~33% quarter-over-quarter from $12.3 million (Q3). The Acute Care franchise increased more than 57% year-over-year in the quarter, signaling clear momentum heading into 2026.
ZYNRELEF Strong Growth and Reimbursement Progress
ZYNRELEF Q4 net sales of $12.5 million (up from $9.3 million in Q3) and 48% year-over-year revenue growth in the quarter. Reimbursement clarity improved with permanent J-code (J0668) and workflow simplifications (VAN rollout); prefilled syringe (PFS) program progressing with potential approval targeted mid- to late-2027.
APONVIE Rapid Adoption and Guideline Inclusion
APONVIE Q4 net sales $3.8 million, up 97% year-over-year; demand units grew ~101% YoY. Included in the Fifth Consensus Guidelines for PONV and granted a permanent product-specific J-code (J8502). Dedicated hospital-focused sales team (IBM group) launched to accelerate hospital adoption.
Successful Financing and Strong Balance Sheet
Completed a financing in 2025 that eliminated a capital-structure overhang, providing financial flexibility to increase targeted commercial investments and execute growth initiatives.
Concrete 2026 Guidance with Continued Profitability Target
Management provided 2026 guidance of $173M–$183M in net product sales and adjusted EBITDA of $10M–$20M, and reiterated an expectation to remain EBITDA positive while making targeted commercial investments to accelerate growth.
Operational Initiatives Driving Commercial Execution
Implemented CrossLink IGNITE incentive program (expanded into 2026), completed VAN rollout to reduce administration friction, and leveraged permanent coding and guideline inclusion to reduce hospital adoption barriers — all cited as drivers of improved distributor/hospital execution.
HRTX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
HRTX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 26, 2026 | $1.08 | $1.20 | +11.11% |
Nov 04, 2025 | $1.18 | $1.14 | -3.39% |
Aug 08, 2025 | $1.84 | $1.32 | -28.26% |
May 06, 2025 | $2.13 | $2.42 | +13.62% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Heron Therapeutics (HRTX) report earnings?
Heron Therapeutics (HRTX) is schdueled to report earning on May 11, 2026, Before Open (Confirmed).
What is Heron Therapeutics (HRTX) earnings time?
Heron Therapeutics (HRTX) earnings time is at May 11, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is HRTX EPS forecast?
HRTX EPS forecast for the fiscal quarter 2026 (Q1) is -0.01.
